IN2009KN04568A - - Google Patents

Download PDF

Info

Publication number
IN2009KN04568A
IN2009KN04568A IN4568KON2009A IN2009KN04568A IN 2009KN04568 A IN2009KN04568 A IN 2009KN04568A IN 4568KON2009 A IN4568KON2009 A IN 4568KON2009A IN 2009KN04568 A IN2009KN04568 A IN 2009KN04568A
Authority
IN
India
Prior art keywords
viral
enzymes
metabolic
animal models
cells
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Shenk
Joshua D Rabinowitz
Josh Munger
Bryson Bennett
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of IN2009KN04568A publication Critical patent/IN2009KN04568A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IN4568KON2009 2007-06-01 2008-06-02 IN2009KN04568A (forum.php)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93276907P 2007-06-01 2007-06-01
US3324308P 2008-03-03 2008-03-03
PCT/US2008/006959 WO2009023059A2 (en) 2007-06-01 2008-06-02 Treatment of viral infections by modulation of host cell metabolic pathways

Publications (1)

Publication Number Publication Date
IN2009KN04568A true IN2009KN04568A (forum.php) 2015-08-28

Family

ID=40351337

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4568KON2009 IN2009KN04568A (forum.php) 2007-06-01 2008-06-02

Country Status (10)

Country Link
US (3) US8158677B2 (forum.php)
EP (3) EP2581081A3 (forum.php)
JP (1) JP5616220B2 (forum.php)
KR (1) KR20100031528A (forum.php)
CN (1) CN101820757A (forum.php)
AU (1) AU2008287542C1 (forum.php)
CA (1) CA2687964A1 (forum.php)
IL (1) IL202403A0 (forum.php)
IN (1) IN2009KN04568A (forum.php)
WO (1) WO2009023059A2 (forum.php)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641766A1 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EP1999119A2 (en) * 2006-02-15 2008-12-10 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
IN2009KN04568A (forum.php) 2007-06-01 2015-08-28 Univ Princeton
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN101869568A (zh) * 2009-04-27 2010-10-27 中国医学科学院基础医学研究所 细胞自噬(ⅱ型细胞凋亡)作用抑制剂的用途
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
JP5753844B2 (ja) 2009-07-08 2015-07-22 ダーミラ（カナダ），インコーポレーテッド 皮膚疾患または病変の治療に有用なｔｏｆａ類似体
EP2536411A4 (en) * 2010-02-18 2013-08-07 Univ Princeton HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM
CN101892226A (zh) * 2010-03-11 2010-11-24 新乡医学院 一种抑制人脂肪细胞ACC基因表达的siRNA及其表达载体和应用
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP2392327A1 (en) * 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
WO2012031763A1 (en) * 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
CN102462674B (zh) * 2010-11-04 2014-04-02 刘丽宏 姜黄素及其衍生物在制备治疗人巨细胞病毒感染药物中的应用
JP2014505076A (ja) * 2011-01-27 2014-02-27 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤としてのｍＴＯＲキナーゼの阻害剤
EP2725902A4 (en) * 2011-04-06 2015-06-24 Univ Princeton ANTIVIRAL COMBINATION THERAPY
WO2012136852A1 (en) * 2011-04-08 2012-10-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for increasing the replication capacity of an influenza virus in cultured cells
DK2723732T3 (en) 2011-06-22 2017-04-03 Purdue Pharma Lp TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND APPLICATIONS THEREOF
EP2726459B1 (en) 2011-07-01 2019-09-11 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
WO2013158820A1 (en) * 2012-04-19 2013-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating viral diseases
CA2927146A1 (en) * 2012-07-03 2014-01-09 Graceland Biotechnology Inc. Compositions and methods for treating and inhibiting viral infections
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US20160220557A1 (en) 2013-09-12 2016-08-04 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EA201690979A1 (ru) * 2013-11-14 2016-08-31 Новира Терапьютикс, Инк. Производные азепана и способы лечения инфекций гепатита в
US20170029436A1 (en) * 2014-04-11 2017-02-02 Helmoltz-Zentrum für Infektionsforschung GmbH Neosoraphens
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
CN104188969A (zh) * 2014-08-13 2014-12-10 广州凯普生物科技有限公司 一种预防和治疗生殖器官癌症的药物及其应用
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
WO2017019636A1 (en) * 2015-07-24 2017-02-02 Insmed Incorporated Compositions and methods for the treatment of sarcoidosis
EP3368663B1 (en) * 2015-11-01 2022-06-01 Glycobac, LLC Virus-free cell lines and methods for obtaining same
US20190355459A1 (en) * 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
EP3430548A1 (en) * 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
CN105794561B (zh) * 2016-03-23 2019-01-01 浙江省农业科学院 油菜素唑提高水稻抗水稻黑条矮缩病毒病的应用及方法
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
KR101805394B1 (ko) * 2016-05-27 2017-12-06 전남대학교산학협력단 칼리시바이러스 감염증 예방 또는 치료용 약학 조성물
DK3466934T3 (da) * 2016-05-31 2024-04-15 Taiho Pharmaceutical Co Ltd Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
JPWO2018147472A1 (ja) * 2017-02-09 2020-01-16 学校法人慶應義塾 血中バイオマーカー
WO2018191475A1 (en) * 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CA3079959A1 (en) * 2017-10-27 2018-10-26 Transfusion Health, Llc Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
TWI762743B (zh) 2017-11-29 2022-05-01 日商大鵬藥品工業股份有限公司 磺醯胺化合物及其用途
WO2020095260A1 (en) * 2018-11-08 2020-05-14 Universita' Degli Studi Di Torino Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family
CN110506676B (zh) * 2019-08-23 2022-03-08 上海海洋大学 Elovl1基因及其应用
CN110812357B (zh) * 2019-11-06 2022-09-23 山东省农业科学院奶牛研究中心 比阿培南在制备防治牛肠道病毒感染药物中的应用
CN111317737B (zh) * 2020-02-24 2023-02-17 南方医科大学 Acc酶抑制剂cp640184作为治疗和/或预防登革病毒感染的药物及其制药用途
US20240041861A1 (en) * 2020-04-21 2024-02-08 Ned Biosystems, Inc. Compositions and methods for treatment and prophylaxis of viral infections
US11826382B2 (en) * 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US20240091253A1 (en) * 2020-05-01 2024-03-21 Tygrus, LLC THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
WO2021236614A1 (en) * 2020-05-18 2021-11-25 Northwestern University Targeted antiviral drugs
FR3110398B1 (fr) * 2020-05-20 2022-06-03 Centre Nat Rech Scient Composés pour leur utilisation pour la réactivation du VIH dans des cellules latentes infectées par le VIH
WO2021252607A1 (en) * 2020-06-12 2021-12-16 Novomer, Inc. Beta-propiolactone compounds and ring opened beta-propiolactone compounds and uses for same
TW202221120A (zh) * 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
CN111920801A (zh) * 2020-09-18 2020-11-13 郑州大学第一附属医院 表没食子儿茶素没食子酸酯在制备治疗和/或预防埃克病毒感染所致疾病的药物中的用途
US20240000805A1 (en) * 2020-12-14 2024-01-04 Md Vault Llc Methods and pharmaceutical compositions for the treatment and prophylaxis of microbial infectious diseases and associated inflammatory disorders and for the treatment and prophylaxis of aging and associated diseases
CN116583274A (zh) * 2020-12-14 2023-08-11 医学文库有限责任公司 用于治疗和预防微生物感染性疾病和相关炎性障碍的方法和药物组合物
CN113698285B (zh) * 2021-07-28 2023-02-10 浙江海洋大学 一种卤代姜黄素衍生物、其制备方法及其在水产品保鲜上的应用
CN114292851B (zh) * 2022-01-12 2023-08-08 徐州医科大学 抑制Cnr1基因表达的干扰序列、shRNA慢病毒载体及构建方法和应用
WO2023212718A2 (en) * 2022-04-29 2023-11-02 Cornell University Methods of treating a virus infection and methods of inhibiting viral replication
CN115006390B (zh) * 2022-06-27 2024-04-19 国药集团动物保健股份有限公司 一种病毒减毒制剂、其制备方法以及应用
CN115282278A (zh) * 2022-07-13 2022-11-04 山东大学 胆固醇调节剂作为抗原递呈促进剂在乙肝治疗中的应用
IT202200016647A1 (it) * 2022-08-04 2024-02-04 Np1 Srl Composizione farmaceutica per il trattamento e la prevenzione dell'hpv
CN116256418B (zh) * 2022-12-30 2025-04-29 核工业理化工程研究院 一种全氟己烷中碳同位素丰度分析方法及分析系统
CN116183788A (zh) * 2023-01-09 2023-05-30 中国农业大学 一种基于同位素示踪技术结合高分辨质谱的精准代谢流分析tca循环的方法
CN119174772B (zh) * 2024-11-26 2025-02-28 四川省医学科学院·四川省人民医院 果糖-1,6-二磷酸在制备防治单纯疱疹病毒1型感染药物中的应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5612114B2 (forum.php) 1974-06-07 1981-03-18
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
FR2425432A1 (en) 1978-05-10 1979-12-07 Boehringer Ingelheim Lab Antibiotic and antifungal cerulenin derivs. - prepd. from a 5-sulphonyloxy 1,2-isopropylidene xylofuranose
FR2457864A2 (fr) 1979-06-01 1980-12-26 Boehringer Ingelheim Lab Procede de preparation de composes du type cerulenine
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4334913A (en) 1981-03-31 1982-06-15 Union Carbide Corporation Substituted 3-hydroxy-2-cyclohexene-1-one compounds as sugar enhancers for plants
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPS611698A (ja) * 1984-06-12 1986-01-07 Mitsubishi Chem Ind Ltd 新規なコルチコイド誘導体およびその製法
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
HU198005B (en) 1984-12-04 1989-07-28 Sandoz Ag Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5188830A (en) 1987-03-27 1993-02-23 Merck & Co., Inc. Methods for thrombolytic therapy
SE503210C2 (sv) 1987-05-22 1996-04-22 Squibb & Sons Inc Fosforhaltiga HMG- CoA- Reduktasinhibitoret, nya intermediat och sätt
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0358607A3 (de) 1988-09-09 1990-10-31 Gesellschaft für Biotechnologische Forschung mbH (GBF) Mikrobizide makrozyklische Laktonderivate
US4958089A (en) 1988-12-20 1990-09-18 Gazelle Microcircuits, Inc. High output drive FET buffer for providing high initial current to a subsequent stage
US5190969A (en) 1988-12-20 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents
AU621434B2 (en) 1988-12-21 1992-03-12 Merrell Dow Pharmaceuticals Inc. Antiretroviral furan ketones
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE4126999A1 (de) 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9209628D0 (en) 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6069298A (en) 1993-02-05 2000-05-30 Regents Of The University Of Minnesota Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6103664A (en) 1995-09-20 2000-08-15 Basf Aktiengesellschaft Synergistic herbicidal mixtures containing cyclohexenone oxime ethers
ATE303144T1 (de) 1995-11-17 2005-09-15 Univ Johns Hopkins Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
US6124125A (en) 1996-01-08 2000-09-26 Trustees Of Dartmouth College AMP activated protein kinase
US6136964A (en) 1996-03-19 2000-10-24 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
US6300487B1 (en) 1996-03-19 2001-10-09 Cell Therapuetics, Inc. Mammalian lysophosphatidic acid acyltransferase
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030163845A1 (en) 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US20020016216A1 (en) 1999-06-08 2002-02-07 Kenji Kobayashi Golf club
US6383987B1 (en) 1999-12-15 2002-05-07 Basf Aktiengesellschaft Cyclohexenone oxime ether/(glyphosates/gluphosinates) suspension concentrates
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
US7704979B2 (en) 2000-09-01 2010-04-27 The University Of Tennessee Research Foundation Materials and methods for the treatment or prevention of obesity
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
DE10115938A1 (de) 2001-03-30 2002-10-10 Medigene Ag Ges Fuer Molekular Verfahren zur Herstellung von Oxirancarbonsäuren und Derivaten davon
US20080161256A1 (en) 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US6482858B1 (en) * 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
KR20040022449A (ko) 2001-07-12 2004-03-12 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조
US20030144345A1 (en) * 2001-07-27 2003-07-31 Marcel Gubler Treatment of metabolic diseases with soraphen derivatives
WO2003037346A1 (en) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US20030158156A1 (en) 2001-11-21 2003-08-21 Kimberly-Clark Worldwide, Inc. Methods for inhibiting the production of TSST-1
WO2003072602A2 (en) 2001-12-20 2003-09-04 Cellzome Ag Protein complexes and methods for their use
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
DE60301491T2 (de) 2002-02-27 2006-05-18 Pfizer Products Inc., Groton Acc-hemmer
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
EA010484B1 (ru) 2002-07-01 2008-10-30 Фасджен, Ллс. Новые соединения, фармацевтические композиции, содержащие их, и способы их использования
EP1565180A4 (en) 2002-10-31 2008-02-27 Fasgen Llc METHOD FOR INHIBITING CANCER DEVELOPMENT WITH INHIBITORS OF FATTY ACID SYNTHASE
US20060147947A1 (en) 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
US6875781B2 (en) 2003-04-04 2005-04-05 Cell Therapeutics, Inc. Pyridines and uses thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AU2004238289A1 (en) 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
CA2525619A1 (en) 2003-05-16 2005-03-03 Rosetta Inpharmatics, Llc Methods and compositions for rna interference
CA2533899C (en) 2003-07-30 2011-01-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US6994956B2 (en) 2003-08-04 2006-02-07 Bayer Pharmaceuticals Corporation Method for assaying enzyme activity
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
ES2687645T3 (es) 2003-10-27 2018-10-26 Merck Sharp & Dohme Corp. Método de diseño de ARNip para el silenciamiento de genes
AU2004292992A1 (en) 2003-11-24 2005-06-09 Georgia State University Research Foundation, Inc Fused ring dicationic anti-protozoan agents and their prodrugs
BRPI0506749A (pt) 2004-01-12 2007-05-22 Applied Research Systems derivados de tiazol e uso dos mesmos
US7220729B2 (en) 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment
US20060195938A1 (en) 2004-06-15 2006-08-31 Eva-Maria Franken Polynucleotides encoding insect acetyl coenzyme-A carboxylase and uses thereof
US7211423B2 (en) 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
US20060040003A1 (en) * 2004-08-10 2006-02-23 Alvin Needleman Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free
FR2888816B1 (fr) 2005-07-20 2007-08-31 Airbus France Sas Panneau auto-raidi monolithique
ATE510028T1 (de) 2006-03-03 2011-06-15 Univ Paris Diderot Paris 7 Verfahren zum elektrochemischen nachweis von zielnukleinsäuresequenzen
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
IN2009KN04568A (forum.php) * 2007-06-01 2015-08-28 Univ Princeton
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Also Published As

Publication number Publication date
US9029413B2 (en) 2015-05-12
JP2010538968A (ja) 2010-12-16
EP2166843A4 (en) 2010-08-11
AU2008287542B2 (en) 2014-07-31
US9757407B2 (en) 2017-09-12
WO2009023059A3 (en) 2010-01-07
US20160346309A1 (en) 2016-12-01
JP5616220B2 (ja) 2014-10-29
EP2572712A3 (en) 2013-11-20
EP2166843A2 (en) 2010-03-31
US20130065850A1 (en) 2013-03-14
AU2008287542A1 (en) 2009-02-19
IL202403A0 (en) 2010-06-30
AU2008287542C1 (en) 2015-01-22
US8158677B2 (en) 2012-04-17
CN101820757A (zh) 2010-09-01
KR20100031528A (ko) 2010-03-22
EP2581081A3 (en) 2013-07-31
WO2009023059A2 (en) 2009-02-19
CA2687964A1 (en) 2009-02-19
US20090239830A1 (en) 2009-09-24
EP2572712A2 (en) 2013-03-27
EP2581081A2 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
IN2009KN04568A (forum.php)
Lyn et al. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes
Wang et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
Das et al. Design and validation of novel chikungunya virus protease inhibitors
Ramière et al. Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A
Sun et al. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism
Debing et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon
Plassmeyer et al. Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID
Wang et al. In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71
Li et al. Effect of exposure to acute and chronic high-altitude hypoxia on the activity and expression of CYP1A2, CYP2D6, CYP2C9, CYP2C19 and NAT2 in rats
Grobler et al. Accelerated preclinical paths to support rapid development of COVID-19 therapeutics
Testoni et al. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes
Mohammadi-Bardbori et al. Alternative electron acceptors: proposed mechanism of paraquat mitochondrial toxicity
Lacroix et al. The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir
Braun-Sand et al. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics
Ranade et al. Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites
Maseko et al. Comparison of HepaRG and HepG2 cell lines to model mitochondrial respiratory adaptations in non-alcoholic fatty liver disease
Jiang et al. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor
Pogliaghi et al. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients
Rahman et al. In vitro evaluation of structural analogs of diallyl sulfide as novel CYP2E1 inhibitors for their protective effect against xenobiotic-induced toxicity and HIV replication
Osbron et al. Caspase-8 activity mediates TNFα production and restricts Coxiella burnetii replication during murine macrophage infection
Škodová‐Sveráková et al. Lineage‐specific activities of a multipotent mitochondrion of trypanosomatid flagellates
Huss et al. Influence of ATP and ADP on dissociation of the V-ATPase into its V1 and VO complexes
HK1141947A (en) Treatment of viral infections by modulation of host cell metabolic pathways
Awortwe et al. In vitro evaluation of reversible and time-dependent inhibitory effects of Kalanchoe crenata on CYP2C19 and CYP3A4 activities